GARDP’s mission is to develop and ensure responsible and sustainable access to new treatments for bacterial infections to address the public health impact of antibiotic resistance. The COVID-19 pandemic has taught us once again that innovation does not necessarily lead to access to life-saving health products. GARDP is committed to working to make sure that the innovation we support results in equitable and rapid access for the patients, health workers, and health systems that need them. We will work with partners at the national and global level to address access barriers from registration and pricing to distribution and appropriate use to make sure that needed treatments can get to people and save lives.
At the 2021 World Anti-Microbial Resistance Congress in Washington DC, GARDP, Shionogi, and the Clinton Health Access Initiative (CHAI) announced their MOU to provide affordable, rational, and sustainable access to cefiderocol. Cefiderocol is an antibiotic that has activity against many of the pathogens on the WHO Priority Pathogen List and is already USFDA and EMA approved and on the WHO Essential Medicines List. GARDP will work across the product to patient pathway to remove access barriers, while strengthening national and regional networks to help introduce this important treatment in a responsible way.
The burden of infectious diseases and drug resistance is highest in low- and middle-income countries. Addressing the pandemic of drug resistance will require global action to ensure lifesaving and lifechanging antibiotics are responsibly and sustainably available for every person who needs them, wherever they live. The SECURE initiative has been developed to address this challenge by expanding access to essential antibiotics for countries and populations in need, while ensuring their appropriate use.
SECURE’s mission is to expand access to essential antibiotics to support countries in addressing the silent pandemic of drug-resistant bacterial infections. Through this initiative, participating countries will have access to essential new antibiotics designed to address drug-resistant infections, alongside essential older antibiotics not widely available or subject to frequent supply chain disruptions. Through increasing access to essential antibiotics, SECURE will help to tackle bacterial diseases and address the rising problem of drug resistance that kills 700,000 people every year.
SECURE is being developed by GARDP and World Health Organization (WHO), with support from UNICEF and the Clinton Health Access Initiative (CHAI) with the aim of building a global consortium of organizations and interested countries that will structure and implement the programmes.
GARDP and Thailand Ministry of Public Health Sign Access and Stewardship MOU
In September 2021, GARDP and the Department of Disease Control of the Thailand Ministry of Public Health (Thai DDC) announced they had signed a MOU to explore opportunities to improve gonorrhoea treatment in Thailand, with the intention to develop an access and stewardship strategy to ensure new antibiotics, such as zoliflodacin, will be available as early as possible in the country.